Oncolytics reports long-lasting survival data for anal cancer drug combo
Oncolytics Biotech's updated Phase 1/2 study shows a 15-month median duration of response for pelareorep combined with an immuno-oncology therapy in anal cancer, surpassing the current standard of care.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed